Recent Advances of Glucocorticoids in the Treatment of Duchenne Muscular Dystrophy (Review)

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2021 Mar 29

PMID 33777191

Citations 13

Authors

Tianyuan Zhang

Xiangdong Kong

Affiliations

Soon will be listed here.

Abstract

Duchenne muscular dystrophy (DMD) is the most common degenerative neuromuscular disease. The incidence of DMD in live births is 1/3,600-1/6,000. Although glucocorticoid-dependent medication is the mainstay treatment option for DMD, a standard treatment regimen has yet to be determined. The present review discusses the literature on the timing, methods and courses of glucocorticoid treatment for DMD. The review highlights the importance of the immediate commencement of glucocorticoid treatment following the diagnosis of DMD, with weekend-only administration being advantageous. Adherence to long-term single-glucocorticoid therapy can delay the loss of ambulation ability, and the side effects of the treatment are controllable. However, the standard medication for patients of different ages and stages of disease development, and the use of combination therapy require further investigation.

Citing Articles

Factors associated with lower forced vital capacity in children and adults with Duchenne muscular dystrophy using non-invasive ventilation: a multicenter analysis.

Sunkonkit K, Hurvitz M, Defante A, Orr J, Chakraborty A, Amin R Sleep Breath. 2025; 29(1):68.

PMID: 39775224 PMC: 11706914. DOI: 10.1007/s11325-024-03183-1.

Inhibition of Mitochondrial Fission Protein Drp1 Ameliorates Myopathy in the D2-mdx Model of Duchenne Muscular Dystrophy.

Rosen H, Berger N, Hodge S, Fujishiro A, Lourie J, Kapadia V bioRxiv. 2025; .

PMID: 39763900 PMC: 11703253. DOI: 10.1101/2024.12.26.628172.

GSK3 inhibition improves skeletal muscle function and whole-body metabolism in male mouse models of Duchenne muscular dystrophy.

Marcella B, Hockey B, Braun J, Whitley K, Geromella M, Baranowski R Nat Commun. 2024; 15(1):10210.

PMID: 39587049 PMC: 11589163. DOI: 10.1038/s41467-024-53886-y.

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.

Kucharska A, Witkowska-Sedek E, Erazmus M, Artemniak-Wojtowicz D, Krajewska M, Pyrzak B Int J Mol Sci. 2024; 25(18).

PMID: 39337654 PMC: 11432634. DOI: 10.3390/ijms251810169.

Respiratory performance in Duchenne muscular dystrophy: Clinical manifestations and lessons from animal models.

Delaney R, OHalloran K Exp Physiol. 2024; 109(9):1426-1445.

PMID: 39023735 PMC: 11363095. DOI: 10.1113/EP091967.

References

Jensen L, Petersson S, Illum N, Laugaard-Jacobsen H, Thelle T, Jorgensen L . Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy. J Musculoskelet Neuronal Interact. 2017; 17(2):8-18. PMC: 5492315. View

Kumaki D, Nakamura Y, Sakai N, Kosho T, Nakamura A, Hirabayashi S . Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report. JBJS Case Connect. 2018; 8(2):e22. DOI: 10.2106/JBJS.CC.17.00190. View

Baltgalvis K, Call J, Nikas J, Lowe D . Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve. 2009; 40(3):443-54. PMC: 2879072. DOI: 10.1002/mus.21327. View

Annexstad E, Fagerheim T, Holm I, Rasmussen M . Molecular and Clinical Characteristics of a National Cohort of Paediatric Duchenne Muscular Dystrophy Patients in Norway. J Neuromuscul Dis. 2019; 6(3):349-359. DOI: 10.3233/JND-190402. View

Wood C, Cheetham T, Guglieri M, Bushby K, Owen C, Johnstone H . Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy. Neuropediatrics. 2015; 46(6):371-6. DOI: 10.1055/s-0035-1563696. View

Sato Y, Yamauchi A, Urano M, Kondo E, Saito K . Corticosteroid therapy for duchenne muscular dystrophy: improvement of psychomotor function. Pediatr Neurol. 2013; 50(1):31-7. DOI: 10.1016/j.pediatrneurol.2013.07.022. View

Ma J, McMillan H, Karaguzel G, Goodin C, Wasson J, Matzinger M . The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2016; 28(2):597-608. DOI: 10.1007/s00198-016-3774-5. View

Vianello S, Pantic B, Fusto A, Bello L, Galletta E, Borgia D . SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells. Hum Mol Genet. 2017; 26(17):3342-3351. DOI: 10.1093/hmg/ddx218. View

Lim K, Maruyama R, Yokota T . Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017; 11:533-545. PMC: 5338848. DOI: 10.2147/DDDT.S97635. View

10.

Hu J, Ye Y, Kong M, Hong S, Cheng L, Wang Q . Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle Nerve. 2015; 52(6):1001-7. DOI: 10.1002/mus.24665. View

11.

Birnkrant D, Bushby K, Bann C, Apkon S, Blackwell A, Colvin M . Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018; 17(5):445-455. PMC: 5902408. DOI: 10.1016/S1474-4422(18)30026-7. View

12.

Tandon A, Villa C, Hor K, Jefferies J, Gao Z, Towbin J . Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc. 2015; 4(4). PMC: 4579941. DOI: 10.1161/JAHA.114.001338. View

13.

McDonald C, Henricson E, Abresch R, Duong T, Joyce N, Hu F . Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2017; 391(10119):451-461. DOI: 10.1016/S0140-6736(17)32160-8. View

14.

Crabtree N, Adams J, Padidela R, Shaw N, Hogler W, Roper H . Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen. Bone. 2018; 116:181-186. DOI: 10.1016/j.bone.2018.07.019. View

15.

Archer J, Vargas C, Anderson J . Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 2006; 20(6):738-40. DOI: 10.1096/fj.05-4821fje. View

16.

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur A . Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016; (5):CD003725. PMC: 8580515. DOI: 10.1002/14651858.CD003725.pub4. View

17.

Manzur A, Kuntzer T, Pike M, Swan A . Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008; (1):CD003725. DOI: 10.1002/14651858.CD003725.pub3. View

18.

Griggs R, Miller J, Greenberg C, Fehlings D, Pestronk A, Mendell J . Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016; 87(20):2123-2131. PMC: 5109941. DOI: 10.1212/WNL.0000000000003217. View

19.

Conklin L, Damsker J, Hoffman E, Jusko W, Mavroudis P, Schwartz B . Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 2018; 136:140-150. PMC: 6218284. DOI: 10.1016/j.phrs.2018.09.007. View

20.

Abutaleb A, McNally E, Khan S, Anderson A, Carr J, Wilcox J . Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids. JAMA Cardiol. 2018; 3(10):1006-1010. PMC: 6233819. DOI: 10.1001/jamacardio.2018.2695. View